|
|
Latest News
In the end, clinical development comes down to biostatistics and words—words in the protocol, the study report, the regulatory filings, and the drug label. In a global world, getting those words right can be no small matter. Mark Uehling discusses translation and regulatory issues facing the drug development process and health care industry with Inna Kassatkina and David Bernstein for his piece at ClinPage.com. Find out more.
|